Botox nabota

This Nabota type A botulinum toxin is indicated for the treatment of blepharospasm associated with dystonia (benign essential blepharospasm, hemifacial spasm, or seventh nerve disorders), to correct strabismus in patients over 12 years of age, or to treat spasmodic torticollis. (also called cervical dystonia) in adults, to treat dynamic clubfoot deformities due to spasticity in pediatric patients with cerebral palsy and, of course, to temporarily treat glabellar lines associated with muscle activity in adult patients under the age of 65 years old. In fact, the treatment is also indicated to temporarily cure focal spasticity and that associated with stroke, again in adulthood.

What is Nabota's function is to bind the receptors to the distal end of the nerve by entering the nerve endings. In this way, we are able to inhibit the natural secretion of a substance called acetylcholine and limit nerve conduction. Nabota is injected through an intramuscular injection, it causes localized muscle paralysis. The puncture will be performed at precise injection points, thus causing localized muscle paralysis by the action of chemical denervation. In doing so, the muscles themselves weaken without ceasing to develop and can generate new nerves and new nerve stimulations over time. But keep in mind that for this very reason, any treatment involving botulinum toxin cannot be definitive.

Several clinical studies have shown that subjects with glabellar lines treated with a five-fold intramuscular injection of 0.1 mL (4 U / 0.1 mL) for a total of 20 IU of Nabota, had improvements between the first 2 and first 5 days of the first treatment, in some cases, improvements were seen after 14 days. Improvement of glabellar lines at rest was observed in 51.2% of subjects, 2 days after administration and the percentage of subjects showing improvement increased over time, with no particular side effects other than those normally encountered in botulinum toxin treatment. type A.

Each neurotoxin treatment can have unpleasant effects, therefore there are precautions to be observed in order to avoid contamination and reduce the risk of contracting botulism and the ineffectiveness of Nabota. The vials must be stored in the refrigerator at a temperature between two and 8 degrees centigrade. If the drug has been activated and diluted with the solution, it must be administered no later than 24 hours, well stored in the refrigerator always at the same temperature.

All vials that have passed the expiration date or those that have been in direct contact with the product should be disposed of and disposed of as if they were medical waste. However, the rules of the nation must still be observed, so if it provides for the inactivation of the toxin before proceeding with disposal, a hypochlorite solution diluted in a proportion between 0.5 and 1% can be used.

There may be adverse reactions or particular symptoms after treatment with Nabota that may involve the skin or the respiratory system. If so, it is best to call your doctor especially if you have difficulty swallowing or speaking, or have difficulty breathing or muscle weakness within hours or weeks of the day of treatment.